chr2-233767092-G-A
Position:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_007120.3(UGT1A4):c.926G>A(p.Gly309Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000274 in 1,461,826 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: not found (cov: 32)
Exomes 𝑓: 0.0000027 ( 0 hom. )
Consequence
UGT1A4
NM_007120.3 missense
NM_007120.3 missense
Scores
16
2
1
Clinical Significance
Conservation
PhyloP100: 9.19
Genes affected
UGT1A4 (HGNC:12536): (UDP glucuronosyltransferase family 1 member A4) This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. This enzyme has some glucuronidase activity towards bilirubin, although is is more active on amines, steroids, and sapogenins. [provided by RefSeq, Jul 2008]
UGT1A5 (HGNC:12537): (UDP glucuronosyltransferase family 1 member A5) This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. [provided by RefSeq, Jul 2008]
UGT1A3 (HGNC:12535): (UDP glucuronosyltransferase family 1 member A3) This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. Substrates of this enzyme include estrone, 2-hydroxyestrone, and metabolites of benzo alpha-pyrene. [provided by RefSeq, Jul 2008]
UGT1A1 (HGNC:12530): (UDP glucuronosyltransferase family 1 member A1) This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The preferred substrate of this enzyme is bilirubin, although it also has moderate activity with simple phenols, flavones, and C18 steroids. Mutations in this gene result in Crigler-Najjar syndromes types I and II and in Gilbert syndrome. [provided by RefSeq, Jul 2008]
UGT1A6 (HGNC:12538): (UDP glucuronosyltransferase family 1 member A6) This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The enzyme encoded by this gene is active on phenolic and planar compounds. Alternative splicing in the unique 5' end of this gene results in two transcript variants. [provided by RefSeq, Jul 2008]
UGT1A10 (HGNC:12531): (UDP glucuronosyltransferase family 1 member A10) This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The enzyme encoded by this gene has glucuronidase activity on mycophenolic acid, coumarins, and quinolines. [provided by RefSeq, Jul 2008]
UGT1A8 (HGNC:12540): (UDP glucuronosyltransferase family 1 member A8) This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The enzyme encoded by this gene has glucuronidase activity with many substrates including coumarins, phenols, anthraquinones, flavones, and some opioids. [provided by RefSeq, Jul 2008]
UGT1A7 (HGNC:12539): (UDP glucuronosyltransferase family 1 member A7) This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The enzyme encoded by this gene has moderate glucuronidase activity with phenols. [provided by RefSeq, Jul 2008]
UGT1A9 (HGNC:12541): (UDP glucuronosyltransferase family 1 member A9) This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The enzyme encoded by this gene is active on phenols. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.99
PP5
Variant 2-233767092-G-A is Pathogenic according to our data. Variant chr2-233767092-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 12272.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr2-233767092-G-A is described in Lovd as [Pathogenic]. Variant chr2-233767092-G-A is described in Lovd as [Pathogenic]. Variant chr2-233767092-G-A is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
UGT1A4 | NM_007120.3 | c.926G>A | p.Gly309Glu | missense_variant | 2/5 | ENST00000373409.8 | NP_009051.1 | |
UGT1A5 | NM_019078.2 | c.926G>A | p.Gly309Glu | missense_variant | 2/5 | ENST00000373414.4 | NP_061951.1 | |
UGT1A3 | NM_019093.4 | c.926G>A | p.Gly309Glu | missense_variant | 2/5 | ENST00000482026.6 | NP_061966.1 | |
UGT1A1 | NM_000463.3 | c.923G>A | p.Gly308Glu | missense_variant | 2/5 | ENST00000305208.10 | NP_000454.1 | |
UGT1A6 | NM_001072.4 | c.920G>A | p.Gly307Glu | missense_variant | 2/5 | ENST00000305139.11 | NP_001063.2 | |
UGT1A10 | NM_019075.4 | c.914G>A | p.Gly305Glu | missense_variant | 2/5 | ENST00000344644.10 | NP_061948.1 | |
UGT1A8 | NM_019076.5 | c.914G>A | p.Gly305Glu | missense_variant | 2/5 | ENST00000373450.5 | NP_061949.3 | |
UGT1A7 | NM_019077.3 | c.914G>A | p.Gly305Glu | missense_variant | 2/5 | ENST00000373426.4 | NP_061950.2 | |
UGT1A9 | NM_021027.3 | c.914G>A | p.Gly305Glu | missense_variant | 2/5 | ENST00000354728.5 | NP_066307.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
UGT1A4 | ENST00000373409.8 | c.926G>A | p.Gly309Glu | missense_variant | 2/5 | 1 | NM_007120.3 | ENSP00000362508.4 | ||
UGT1A5 | ENST00000373414.4 | c.926G>A | p.Gly309Glu | missense_variant | 2/5 | 1 | NM_019078.2 | ENSP00000362513.3 | ||
UGT1A3 | ENST00000482026.6 | c.926G>A | p.Gly309Glu | missense_variant | 2/5 | 1 | NM_019093.4 | ENSP00000418532.1 | ||
UGT1A1 | ENST00000305208.10 | c.923G>A | p.Gly308Glu | missense_variant | 2/5 | 1 | NM_000463.3 | ENSP00000304845.5 | ||
UGT1A6 | ENST00000305139.11 | c.920G>A | p.Gly307Glu | missense_variant | 2/5 | 1 | NM_001072.4 | ENSP00000303174.6 | ||
UGT1A10 | ENST00000344644.10 | c.914G>A | p.Gly305Glu | missense_variant | 2/5 | 1 | NM_019075.4 | ENSP00000343838.5 | ||
UGT1A9 | ENST00000354728.5 | c.914G>A | p.Gly305Glu | missense_variant | 2/5 | 1 | NM_021027.3 | ENSP00000346768.4 | ||
UGT1A7 | ENST00000373426.4 | c.914G>A | p.Gly305Glu | missense_variant | 2/5 | 1 | NM_019077.3 | ENSP00000362525.3 | ||
UGT1A8 | ENST00000373450.5 | c.914G>A | p.Gly305Glu | missense_variant | 2/5 | 1 | NM_019076.5 | ENSP00000362549.4 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD3 exomes AF: 0.0000120 AC: 3AN: 249004Hom.: 0 AF XY: 0.00000742 AC XY: 1AN XY: 134794
GnomAD3 exomes
AF:
AC:
3
AN:
249004
Hom.:
AF XY:
AC XY:
1
AN XY:
134794
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000274 AC: 4AN: 1461826Hom.: 0 Cov.: 33 AF XY: 0.00000275 AC XY: 2AN XY: 727212
GnomAD4 exome
AF:
AC:
4
AN:
1461826
Hom.:
Cov.:
33
AF XY:
AC XY:
2
AN XY:
727212
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Mar 29, 2023 | PP3, PP4, PM2, PM3, PS3, PS4_moderate - |
Likely pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Aug 18, 2022 | The UGT1A1 c.923G>A; p.Gly308Glu variant (rs62625011), also known as p.Gly309Glu and UGT1A1*11, is reported in the literature in the homozygous state in two individuals affected with Crigler-Najjar syndrome (Erps 1994, Gaidos 2006), and in the compound heterozygous state in five individuals affected with Gilbert syndrome and one affected with Crigler-Najjar syndrome (Costa 2006, Rodrigues 2012). In vitro functional analysis demonstrates reduced enzyme activity (Erps 1994). This variant is reported in ClinVar (Variation ID: 12272) but is only observed on three alleles in the Genome Aggregation Database, indicating it is not a common polymorphism. The glycine at codon 308 is moderately conserved and computational analyses predict that this variant is deleterious (REVEL: 0.949). Based on available information, this variant is considered to be likely pathogenic. References: Costa E et al. Analysis of the UDP-glucuronosyltransferase gene in Portuguese patients with a clinical diagnosis of Gilbert and Crigler-Najjar syndromes. Blood Cells Mol Dis. 2006 Jan-Feb;36(1):91-7. PMID: 16269258. Erps LT et al. Identification of two single base substitutions in the UGT1 gene locus which abolish bilirubin uridine diphosphate glucuronosyltransferase activity in vitro. J Clin Invest. 1994 Feb;93(2):564-70. PMID: 7906695. Gajdos V et al. Successful pregnancy in a Crigler-Najjar type I patient treated by phototherapy and semimonthly albumin infusions. Gastroenterology. 2006 Sep;131(3):921-4. PMID: 16952560. Rodrigues C et al. Impact of UGT1A1 gene variants on total bilirubin levels in Gilbert syndrome patients and in healthy subjects. Blood Cells Mol Dis. 2012 Mar 15;48(3):166-72. PMID: 22325916. - |
Gilbert syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Mendelics | May 04, 2022 | - - |
UGT1A1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 16, 2024 | The UGT1A1 c.923G>A variant is predicted to result in the amino acid substitution p.Gly308Glu. This variant has been reported in the homozygous or compound heterozygous state in individuals with Gilbert syndrome, or Crigler-Najjar syndrome I or II (reported as Gly309Glu in Erps et al 1994. PubMed ID: 7906695; Costa et al 2006. PubMed ID: 16269258; Rodrigues et al 2012. PubMed ID: 22325916). This variant is reported in 0.0087% of alleles in individuals of Latino descent in gnomAD. This variant is interpreted as pathogenic. - |
Crigler-Najjar syndrome type 1 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 01, 1994 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
D;D;.;D;D;.;D;.;D;D;D;D;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Pathogenic
D;D;D;D;D;D;D;D;D;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D;D;D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
.;.;.;H;.;.;.;.;.;.;.;.;.
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;D;D;D;D;D;D;D;D;D;D;D;D
REVEL
Pathogenic
Sift
Pathogenic
D;D;D;D;D;D;D;D;D;D;D;D;D
Sift4G
Pathogenic
D;D;D;D;D;D;D;D;D;D;D;D;D
Polyphen
D;D;.;D;D;.;D;.;D;D;D;D;.
Vest4
MutPred
0.97
.;.;.;.;.;.;.;.;Gain of catalytic residue at G309 (P = 0.0075);Gain of catalytic residue at G309 (P = 0.0075);Gain of catalytic residue at G309 (P = 0.0075);.;.;
MVP
MPC
0.23, 0.37, 0.60, 0.54, 0.78, 0.23, 0.22, 0.63
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at